PR91507

BENGALURU, India, Sept. 7,2021/PRNewswire=KYODO JBN/--

    Today, Jubilant Biosys Limited announced the appointment of Giuliano

Perfetti as its Chief Executive Officer.

    Mr. Perfetti has more than 20 years of experience across diverse businesses

and global markets with expertise in Strategy, Sales, Marketing and Business

Development. He has led business transformation and expansion programs working

in reputed names including Accenture and Astrazeneca among others. Prior to

joining Jubilant Biosys, Mr. Perfetti was associated with Fabbrica Italiana

Sintetici (F.I.S) as Chief Commercial Officer and was responsible for

strategizing and executing the company's growth plan and ramping up the global

scale-up and commercial service business.

    Commenting on his joining, Mr. Shyam S Bhartia, Chairman and Mr Hari S

Bhartia Co-Chairman and Managing Director, Jubilant Pharmova, said, "Jubilant

Biosys is delighted to have Giuliano come on board as we make rapid progress in

expanding our drug discovery services and CDMO business through investments in

infrastructure and new capacity."

    "I am thrilled to be joining the Jubilant Bhartia Group at such a pivotal

time of growth and investment bringing a fully integrated offering from Drug

Discovery to Development and Commercial Production," said Mr. Giuliano Perfetti

on his appointment.

    About Jubilant Biosys Limited

    Jubilant Biosys, a subsidiary of Jubilant Pharmova Limited, an integrated

global pharmaceutical company, has presence in Bengaluru and Noida in India.

Jubilant Biosys offers contract research & development services for global

pharmaceutical innovators. Jubilant Biosys has demonstrated expertise in

functional services in chemistry including- computational, medicinal/ synthetic

chemistry, PR&D and GMP scale-up capabilities up to phase II. Services in

biology include structural biology, in-vitro biology, DMPK, in-vivo

pharmacology and Toxicology. Further, Jubilant Biosys has integrated discovery

expertise with a track record of working on over 80 programs in multiple

therapeutic areas including but not limited to Oncology, Metabolic Disorders,

Pain & Inflammation, CNS and expanding into Rare Diseases.

    For more info: www.jubilantbiosys.com

    About Jubilant Pharmova Limited

    Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a

company engaged in pharmaceuticals, contract research and development services

and proprietary novel drugs businesses. Pharmaceuticals business through

Jubilant Pharma Limited Singapore (JPL) is engaged in manufacturing and supply

of Radiopharmaceuticals with a network of 48 radio-pharmacies in the US,

Allergy Therapy Products, Contract Manufacturing of Sterile Injectibles and

Non-sterile products, APIs and Solid Dosage Formulations through six USFDA

approved manufacturing facilities in the US, Canada and India. Jubilant Biosys

Limited provides Contract Research and Development Services through three world

class research centres in Bangalore, Noida and Greater Noida in India. Jubilant

Therapeutics is involved in Proprietary Novel Drugs business and is an

innovative biopharmaceutical company developing breakthrough therapies in the

area of oncology and auto-immune disorders. Jubilant Pharmova Limited has a

team of around 5,800 multicultural people across the globe. The Company is well

recognized as a 'Partner of Choice' by leading pharmaceuticals companies

globally. For more information, please visit: www.jubilantpharmova.com.

    Logo: https://mma.prnewswire.com/media/821405/Jubilant_Biosys_Logo.jpg

    Photo:

https://mma.prnewswire.com/media/1609414/Mr_Giuliano_Perfetti_CEO_Jubilant.jpg

    Source: Jubilant Biosys Limited